Drugs / MEDI-560
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00508651 | Oct 2007 → Apr 2009 | — | MedImmune LLC | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI-560 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00508651 ↗ |
| Modality | Vaccine | “A live, attenuated recombinant parainfluenza virus type 3 (PIV3) vaccine” NCT00508651 ↗ |
| Route | Intranasal | “Administered Intranasally” NCT00508651 ↗ |